Подписаться
Liyang Diao
Liyang Diao
Неизвестная организация
Нет подтвержденного адреса электронной почты - Главная страница
Название
Процитировано
Процитировано
Год
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
P Feuerstadt, TJ Louie, B Lashner, EEL Wang, L Diao, JA Bryant, M Sims, ...
New England Journal of Medicine 386 (3), 220-229, 2022
2652022
Changes in vaginal community state types reflect major shifts in the microbiome
JP Brooks, GA Buck, G Chen, L Diao, DJ Edwards, JM Fettweis, ...
Microbial ecology in health and disease 28 (1), 1303265, 2017
912017
A phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis
MR Henn, EJ O’Brien, L Diao, BG Feagan, WJ Sandborn, C Huttenhower, ...
Gastroenterology 160 (1), 115-127. e30, 2021
662021
Sporulation genes associated with sporulation efficiency in natural isolates of yeast
P Tomar, A Bhatia, S Ramdas, L Diao, G Bhanot, H Sinha
PLoS One 8 (7), e69765, 2013
302013
Local Ancestry Corrects for Population Structure in Saccharomyces cerevisiae Genome-Wide Association Studies
L Diao, KC Chen
Genetics 192 (4), 1503-1511, 2012
282012
MixMir: microRNA motif discovery from gene expression data using mixed linear models
L Diao, A Marcais, S Norton, KC Chen
Nucleic acids research 42 (17), e135-e135, 2014
222014
Multiple roles of PIWIL1 in mouse neocorticogenesis
B Viljetic, L Diao, J Liu, Z Krsnik, SHR Wijeratne, R Kristopovich, ...
bioRxiv, 106070, 2017
82017
P421 SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in a placebo-controlled, double-blind randomised trial in patients with …
B Misra, J Curran, H Herfarth, K Jagarlamudi, C Oneto, BR Bhandari, ...
Journal of Crohn's and Colitis 12 (supplement_1), S317-S317, 2018
72018
85-Ser-287, an investigational Microbiome therapeutic, induces remission and endoscopic improvement in a Placebo-controlled, Double-Blind randomized trial in Patients with …
M Bharat, J Curran, HH Herfarth, K Jagarlamudi, C Oneto, BR Bhandari, ...
Gastroenterology (New York, NY 1943) 154 (6), S-25-S-25, 2018
62018
The shuffle index and evaluation of models of signal transduction pathways
EE Allen, L Diao, JS Fetrow, DJ John, RF Loeser, LB Poole
Proceedings of the 45th annual southeast regional conference, 250-255, 2007
62007
1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes
C Ford, M Henn, J Bryant, L Diao, J Wortman, A Tomlinson, K Litcofsky, ...
Open Forum Infectious Diseases 5 (suppl_1), S46-S47, 2018
52018
623–Ser-287, an investigational microbiome therapeutic, induces widespread transcriptional changes related to clinical remission in a placebo-controlled, double-blind …
L Diao, MC Nnamani, E OBrien, C Desjardins, A Martinez, S Simmons, ...
Gastroenterology 156 (6), S-130, 2019
42019
Tu2019-Engraftment of Ser-287, an Investigational Microbiome Therapeutic, is Related to Clinical Remission in a Placebo-Controlled, Double-Blind Randomized Trial (Seres-101) in …
S Simmons, L Diao, E O'Brien, M Chafee, J Zhao, P Bernardo, D Cook, ...
Gastroenterology 154 (6), S-1371-S-1372, 2018
42018
Rapid conversion of primary to secondary bile acids in subjects with recurrent Clostridioides difficile infection (CDI) following SER-109, an investigational microbiome therapeutic
JA Bryant, L Diao, EJ O’Brien, CB Ford, KD Litcofsky, JR Wortman, ...
Digestive Disease Week, virtual, May, 21-23, 2021
32021
Designed bacterial compositions and uses thereof
A Martinez, EJ O'brien, SL Simmons, D Cook
32019
Statistical Modeling in Biomedical Research
Y Zhao, DGD Chen
Springer International Publishing, 2020
22020
621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner
M Henn, C Ford, E O’Brien, J Wortman, L Diao, C Desjardins, ...
Open Forum Infectious Diseases 5 (suppl_1), S226-S227, 2018
22018
Gastrointestinal tract microbiome dynamics following treatment with SER-109, an investigational oral microbiome therapeutic to reduce the recurrence of Clostridium difficile …
M Henn, C Ford, E O’Brien, J Wortman, S Simmons, L Diao, K Litcofsky, ...
Open Forum Infectious Diseases 4 (suppl_1), S389-S390, 2017
22017
LB15. SER-109, an Investigational Microbiome Therapeutic, Reduces Abundance of Antimicrobial Resistance Genes in Patients with Recurrent Clostridioides Difficile Infection …
TJ Straub, L Diao, C Ford, M Sims, TJ Louie, C Berenson, CS Kraft, ...
Open Forum Infectious Diseases 8 (Supplement_1), S812-S813, 2021
12021
681 SER-301, AN INVESTIGATIONAL, RATIONALLY-DESIGNED BACTERIAL CONSORTIUM FOR MILD-TO-MODERATE ULCERATIVE COLITIS, RECAPITULATES THE EFFECTS OF SER-287, A CONSORTIUM OF …
A Martinez, EJ O'Brien, D Balasubramanian, M Chafee, A Pina, ...
Gastroenterology 160 (6), S-135, 2021
12021
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20